107 related articles for article (PubMed ID: 20973265)
1. Medical costs and outcomes for Australian women with ovarian cancer: a patient-level analysis over 2.5 years.
Gordon LG; Scuffham PA; Beesley VL; Green AC; DeFazio A; Wyld DK; Clavarino AM; ; Webb PM
Int J Gynecol Cancer; 2010 Jul; 20(5):757-65. PubMed ID: 20973265
[TBL] [Abstract][Full Text] [Related]
2. Resource implications of palliative chemotherapy for ovarian cancer.
Doyle C; Stockler M; Pintilie M; Panesar P; Warde P; Sturgeon J; Oza AM
J Clin Oncol; 1997 Mar; 15(3):1000-7. PubMed ID: 9060539
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel: a pharmacoeconomic review of its use in the treatment of ovarian cancer.
Young M; Plosker GL
Pharmacoeconomics; 2001; 19(12):1227-59. PubMed ID: 11772158
[TBL] [Abstract][Full Text] [Related]
4. The end of life costs for Medicare patients with advanced ovarian cancer.
Urban RR; He H; Alfonso R; Hardesty MM; Goff BA
Gynecol Oncol; 2018 Feb; 148(2):336-341. PubMed ID: 29208368
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer.
Poonawalla IB; Lairson DR; Chan W; Piller LB; Du XL
Value Health; 2015 Jun; 18(4):387-95. PubMed ID: 26091592
[TBL] [Abstract][Full Text] [Related]
6. Aggressive and complex surgery for advanced ovarian cancer: an economic analysis.
Aletti GD; Podratz KC; Moriarty JP; Cliby WA; Long KH
Gynecol Oncol; 2009 Jan; 112(1):16-21. PubMed ID: 19027146
[TBL] [Abstract][Full Text] [Related]
7. Palliative therapy in advanced ovarian cancer: balancing patient expectations, quality of life and cost.
Patnaik A; Doyle C; Oza AM
Anticancer Drugs; 1998 Nov; 9(10):869-78. PubMed ID: 9890698
[TBL] [Abstract][Full Text] [Related]
8. Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.
Seagle BL; Graves S; Strohl AE; Shahabi S
Int J Gynecol Cancer; 2017 Oct; 27(8):1610-1618. PubMed ID: 28763362
[TBL] [Abstract][Full Text] [Related]
9. Costs of treatment for elderly women with advanced ovarian cancer in a Medicare population.
Forde GK; Chang J; Ziogas A; Tewari K; Bristow RE
Gynecol Oncol; 2015 Jun; 137(3):479-84. PubMed ID: 25866323
[TBL] [Abstract][Full Text] [Related]
10. Total and out-of-pocket costs of different primary management strategies in ovarian cancer.
Suidan RS; He W; Sun CC; Zhao H; Rauh-Hain JA; Fleming ND; Lu KH; Giordano SH; Meyer LA
Am J Obstet Gynecol; 2019 Aug; 221(2):136.e1-136.e9. PubMed ID: 30965052
[TBL] [Abstract][Full Text] [Related]
11. Variations in adjuvant chemotherapy and survival in women with epithelial ovarian cancer - a population-based study.
Anuradha S; Donovan PJ; Webb PM; Brand AH; Goh J; Friedlander M; Oehler MK; Quinn M; Steer C; Jordan SJ
Acta Oncol; 2016; 55(2):226-33. PubMed ID: 26079434
[TBL] [Abstract][Full Text] [Related]
12. Does palliative chemotherapy palliate? Evaluation of expectations, outcomes, and costs in women receiving chemotherapy for advanced ovarian cancer.
Doyle C; Crump M; Pintilie M; Oza AM
J Clin Oncol; 2001 Mar; 19(5):1266-74. PubMed ID: 11230467
[TBL] [Abstract][Full Text] [Related]
13. Impact of obesity on chemotherapy dosing for women with advanced stage serous ovarian cancer in the Australian Ovarian Cancer Study (AOCS).
Au-Yeung G; Webb PM; DeFazio A; Fereday S; Bressel M; Mileshkin L
Gynecol Oncol; 2014 Apr; 133(1):16-22. PubMed ID: 24680586
[TBL] [Abstract][Full Text] [Related]
14. Can we maximize both value and quality in gynecologic cancer care? A work in progress.
Havrilesky LJ; Fountain C
Am Soc Clin Oncol Educ Book; 2014; ():e268-75. PubMed ID: 24857112
[TBL] [Abstract][Full Text] [Related]
15. [Economic assessment of Caelyx versus topotecan in advanced ovarian cancer].
Girre V; Pujade-Lauraine E; Durand-Zaleski I
Bull Cancer; 2003 Nov; 90(11):983-8. PubMed ID: 14706902
[TBL] [Abstract][Full Text] [Related]
16. Primary cytoreductive surgery and adjuvant hormonal monotherapy in women with advanced low-grade serous ovarian carcinoma: Reducing overtreatment without compromising survival?
Fader AN; Bergstrom J; Jernigan A; Tanner EJ; Roche KL; Stone RL; Levinson KL; Ricci S; Wethingon S; Wang TL; Shih IM; Yang B; Zhang G; Armstrong DK; Gaillard S; Michener C; DeBernardo R; Rose PG
Gynecol Oncol; 2017 Oct; 147(1):85-91. PubMed ID: 28768570
[TBL] [Abstract][Full Text] [Related]
17. Influence of the gynecologic oncologist on the survival of ovarian cancer patients.
Chan JK; Kapp DS; Shin JY; Husain A; Teng NN; Berek JS; Osann K; Leiserowitz GS; Cress RD; O'Malley C
Obstet Gynecol; 2007 Jun; 109(6):1342-50. PubMed ID: 17540806
[TBL] [Abstract][Full Text] [Related]
18. Advances in the management of epithelial ovarian cancer.
Berkenblit A; Cannistra SA
J Reprod Med; 2005 Jun; 50(6):426-38. PubMed ID: 16050567
[TBL] [Abstract][Full Text] [Related]
19. A systematic overview of chemotherapy effects in ovarian cancer.
Högberg T; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
[TBL] [Abstract][Full Text] [Related]
20. Cost-utility comparison of neoadjuvant chemotherapy versus primary debulking surgery for treatment of advanced-stage ovarian cancer in patients 65 years old or older.
Rowland MR; Lesnock JL; Farris C; Kelley JL; Krivak TC
Am J Obstet Gynecol; 2015 Jun; 212(6):763.e1-8. PubMed ID: 25644442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
